

ROBERT W. HOLLOWAY, MD, FACOG, FACS

CURRICULUM VITAE

PERSONAL:

Home Address: 145 James Place
Maitland, Florida 32751

Business Address: Florida Hospital Cancer Institute
2501 North Orange Avenue
Suite 800
Orlando, FL 32804

Telephone: Home: (407) 622-8774
Work: (407) 303-2422

Date of Birth: July 16, 1957
Place of Birth: Sparta, Illinois
Spouse: Leslie Ruebusch Holloway
Children: Megan, Kara, and Jackson

WORK HISTORY:

07/90 – 11/94 The Watson Clinic
Gynecologic Oncology
1600 Lakeland Hills Boulevard
Lakeland, FL 33804-5000
(813) 680-7193

11/94 – Present Co-Medical Director, Gynecologic Oncology Program
Florida Hospital Cancer Institute, Orlando, FL

Clinical Instructor, Obstetrics and Gynecology Residency Program
Department of Obstetrics and Gynecology
Orlando Regional Medical Center, Orlando, FL

Adjunct Clinical Professor, Department of Obstetrics and
Gynecology
Duke Comprehensive Cancer Center, Durham, NC

07/08 – Present Professor of Obstetrics and Gynecology (Affiliated/Volunteer)
University of Central Florida, College of Medicine, Orlando, FL

08/09 - Present Clinical Professor, Obstetrics & Gynecology
Florida State University, College of Medicine
Orlando Regional Campus, Orlando, FL

EDUCATION:

High School: Sparta Community High School
Sparta, Illinois (May 1975)

Undergraduate: University of Illinois
Champaign-Urbana
B.S., Biology (May 1979)

Medical School: Vanderbilt University
Nashville, Tennessee
M.D., (May 1983)

Residency: University of Alabama at Birmingham
Obstetrics and Gynecology
June 1983 to July 1987)

Fellowship: Georgetown University Hospital
Washington, DC
Gynecology Oncology
(July 1987 to July 1990)

ACCREDITATION:

Diplomate of the National Board of Medical Examiners, 07/84 (665/685/650)

American Board of Obstetrics and Gynecology, 12/91

American Board of Obstetrics and Gynecology, Gynecologic Oncology Certification
12/92. Recertification Exam 2000

Fellowship American College Obstetrics and Gynecology, 01/92

Fellowship American College Surgeons, 10/93

CERTIFICATION:

Certificate of Off-Site Training as a Console Surgeon, da Vinci[®] Surgical System.
Conducted April 13-14, 2006; St. Joseph's Hospital, Atlanta, GA

LICENSES:

Alabama (07/84 - 02/01) AL 11580

Florida (09/90 – Present) 58193

HONORS AND ACTIVITIES:

UNDERGRADUATE:
Liberal Arts and Science Dean's List, 1976-1979

Phi Eta Sigma Honorary, 05/76

Phi Beta Kappa Honorary, 05/78

Phi Kappa Phi Scholarship Award, 05/79

University of Illinois Bronze Tablet Award (Top 3% class rank), 05/79

President, Alpha Delta Phi Fraternity, (1978-1979)

MEDICAL SCHOOL:

Dean's Committee for Educational Programs and Student Affairs

Accreditation Curriculum Evaluation Committee, 1981

Vanderbilt Diabetes Research and Training Center Summer Research Program Coordinator, 1981

Research Assistant (T. Kono, PhD, Physiology), Vanderbilt University, summer 1980

Research Assistant (J. Corbin, PhD, Physiology), Vanderbilt University, summer 1981

RESIDENCY:

American College of Obstetrics and Gynecology (ACOG) – Mead Johnson Fellowship Award, May 1986

Administrative Chief Resident, University of Alabama Hospitals, Department of OB/GYN, 1986-1987

ACOG Junior Fellows Section Vice-Chairman, 09/83–09/94, Section Chairman, 09/84–09/86

ACOG Junior Fellows District VII Treasurer, 09/85–09/86

HONORS:

“Surgeon of the Year” by the Orange County Medical Society (OCMS), 2007.

“Best Doctor” award by Best Doctors of America: 2005, 2006, 2007, 2008, 2009

SGO Best Clinical Practice Poster Award (shared with Drs. S.A. DeNardis, R.W. Holloway, G.E. Bigsby IV, D.P. Pikaart, S. Ahmad, N.J. Finkler), 2008.

PATIENTS' CHOICE Recognition Award (by *MDx Medical Inc., New Jersey*), March 2009.

Journal of Robotic Surgery, Associate Editor, 2006-Current.

Reviewers for Peer-Reviewed Scientific Journals, 1992-Current (British Medical Journal, Gynecologic Oncology, Archives of Obstetrics and Gynecology)

Referee, The Cochrane Library (Cochrane Gynecological Cancer Review Group), London, UK

Program Committee, 42nd Annual Meeting on Women's Cancer of the Society of Gynecologic Oncologists (SGO), March 2011, Orlando, FL

ORGANIZATIONS:

Charles E. Flowers Medical Society

Mid-Atlantic Gynecologic Oncology Society

American Society of Clinical Oncology

Florida Association of Clinical Oncology

American Cancer Society, West Polk Unit, Medical Advisor 1990-1993, President 1993-1994

Florida Obstetric and Gynecologic Society

American College of Obstetrics and Gynecology

American College of Surgeons

Society of Gynecologic Oncologists

- Education Committee, 2005-2007
- Communications/Marketing Committee, 2005-present

Florida Society of Gynecologic Oncologists

- Founding Member, 1994
- Secretary Treasurer, 1995-1998
- President Elect, 1998-2000
- President, 2000-2002

Society of Robotic Surgery, Charter Member

RESEARCH GRANTS SUPPORT:

Completed

08/1985-08/198 Following Cervical Carcinoma Patients with SCC Serum Radioimmunoassay. *Principle Investigators:* Shingleton HM, To A, Holloway RW \$25,000, Abbott Laboratories,

- 08/1987-08/1988 Renewal grant, Abbott Laboratories, Principle investigators: Holloway RW, Delgado G, Barnes W, Barter J. \$20,000.
- 05/1988 Comparison of In Situ Hybridization of Polymerase Chain Reaction for HPV Typing. Holloway RW, Farrell M, Waggoner S, Delgado G, Biomedical Research Support Grant #RR-05360, Georgetown University, \$6,000.
- 2009-2010 Gala Endowed Foundation for Oncologic Research Grant of the Florida Hospital-University of Central Florida Program, *Co-Investigator*, “Pre-Clinical Models to Investigate Cellular Therapy for Ovarian Cancer” PI: Sarfraz Ahmad, Ph.D.); \$20,000.
- 2009-2010 Gala Endowed Foundation for Oncologic Research Grant of the Florida Hospital-University of Central Florida Program, *Co-Principal Investigator*, “Relevance of Stat3 Pathway in Ovarian Cancer: Therapeutic Implications” (PIs: James Turkson, Ph.D. and Robert W. Holloway, M.D.); \$65,000.
- Active**
- 2010-2011 Gala Endowed Foundation for Oncologic Research Grant of the Florida Hospital-University of Central Florida Program, *Co-Investigator*, “MicroRNA Expression Profile of Ovarian Cancer: Correlation to Cellular Therapy Response” (PI: Susan B. Ingersoll, Ph.D.); \$20,000.
- 2010-2011 Gala Endowed Foundation for Oncologic Research Grant of the Florida Hospital-University of Central Florida Program, *Co-Principal Investigator* “Analysis of EGFR-Erk^{mapk} and EGFR-Stat3 Pathway in Recurrent and Resistant Ovarian Cancer” (PIs: James Turkson, Ph.D. and Robert W. Holloway, M.D.); \$45,000.
- 2010-2011 Ovarian Cancer Alliance of Florida (Teresa Rosebrough Research Fund) Starter Grant: *Co-Investigator*, “Investigation of MicroRNA Expression Profile and its Correlation with Ovarian Cancer Response to Cellular Therapy” (PIs: Susan B. Ingersoll, Ph.D.); \$15,000.
- 2009-2012 Florida Department of Health, Bankhead-Coley Cancer Research Program, Florida Biomedical Research Program – New Investigator Research (NIR) Grant, Co-Investigator, “Cellular Therapy in Combination with Cytokines as Treatment of Ovarian Cancer” (PI: Susan B. Ingersoll, Ph.D.); \$374,049.

ABSTRACTS:

1. Corbin JD; Holloway RW: Mechanism of Protein Kinase Activation by Hormones Which Elevates Cyclic AMP. 12th International Congress of Biochemistry, Perth, Australia, 08/15/82.

2. Holloway RW; To A; Shingleton HM: Clinical Utility of the SCC Immunoassay in the Management of Cervical Cancer. American College of Obstetrics and Gynecology (ACOG) District VII Meeting, Little Rock, Arkansas, 10/15/86.
3. Holloway RW; To A; Moradi M; et al: Following Cervical Cancer with the SCC Assay. Society of Gynecologic Oncology (SGO), Miami, Florida 02/07/88.
4. Holloway RW; Lewandowski G; Farrell M; Potkul RK; Jenson A; Lancaster W; Delgado G: Demonstration of Human Papillomavirus (HPV) in Primary, Metastatic and Recurrent Cervical Carcinoma Using in Situ Hybridization. SGO Twentieth Annual Meeting, February, 1989. Gynecologic Oncology 32 (1):112-113, January 1989.
5. Barnes W; Delgado G; Holloway RW; Jenson A; et al: Effects of Human Interferon on HPV Induced Lesions of Human Epithelial Xenografts in Athymic Mice. SGO Twentieth Annual Meeting, February, 1989. Gynecologic Oncology 32(1):114-115, January 1989.
6. Holloway RW; Waggoner S; Delgado G, et al.: Risk Factors Associated with Development of Clostridium difficile Diarrhea on a Gynecologic Oncologic Service. Mid-Atlantic Gynecologic Oncology Society, Fourth Annual Meeting, October 12, 1989. Williamsburg, Virginia.
7. Orr JW; Holloway RW; Orr PF: Surgical Staging of Uterine Cancer: An Analysis of Perioperative Morbidity. SGO Twenty-Second Annual Meeting, February 1991, Orlando, Florida. Gynecologic Oncology 40: 168-193, 1991.
8. Holloway RW; ORR Jr. JW. An Evaluation of Groshong Central Venous Catheters on a Gynecologic Oncologic Service. Mid-Atlantic Gynecologic Oncologic Society, Washington, DC, September 24, 1993.
9. Crawford, EC; Orr Jr JW; Holloway RW; Futrell P, et al.: Comparison of Loss of Heterozygosity of 3p and Cytogenesis between Ovarian Tumors of Low Malignant Potential and Malignant Ovarian Tumors. American Journal of Human Genetics Vol.53 (3): Abstract #28, Supplement September 1993.
10. Holloway RW and Orr, Jr. JW: Experience with the Groshong Catheter on a Gynecologic Oncology Service. The Felix Rutledge Society, Padua, Italy, April 22, 1994.
11. Holloway RW and Orr Jr., JW: Experience with the Groshong Catheter on a Gynecologic Oncology Service. American College of Obstetrics & Gynecology (ACOG) Annual Meeting, Orlando, Florida, May 9, 1994.
12. Mehta RS; Parker RJ; Fruehauf JP; Finkler NJ; Holloway RW: Ovarian Cancer Patients with In Vitro Resistance to Platinum Exhibit Poorer Survival After

- Treatment with Platinum Based Chemotherapy. American Association Cancer Research (AACR) San Francisco, CA April 2000.
13. Rader J; Clarke-Pearson D; Moore M; Carson L; Holloway RW; Kao M-S; Wiznitzer I; Douglass E: Phase II Trial of ZD9331 as Third-Line Therapy for Patients with Ovarian Carcinoma. European Society of Medical Oncology, October 2000.
 14. Holloway RW and Finkler NJ: Phase II Evaluation of OSI-774, A Potent Oral Antagonist of the EGFR-TK in Patients with Advanced Ovarian Carcinoma. ASCO Mascone Center, San Francisco, CA, American Society of Clinical Oncology, May 2001.
 15. Holloway, RW: A Phase I/II Trial of Weekly Topotecan in the Treatment of Advanced Recurrent Metastatic Endometrial Carcinoma. 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, 2002, Orlando, Florida. Abstract 2504.
 16. Holloway RW; Finkler NJ; Nye L; Bigsby IV GE; Ortiz BH: Doxil and Gemcitabine Combination Therapy for Recurrent Ovarian Cancer, Results of a Phase II trial. American Society of Clinical Oncology Annual Conference, June 2004. ASCO Vol 23: 5090, 470.
 17. Bigsby IV GE; Holloway RW; Finkler NJ; Ortiz BH; Sombeck MD: Combination Chemoradiation Followed by Simple Hysterectomy for Treatment of IB-2 Cervical Cancer. Poster Presentation SGO, 2005.
 18. Pikaart DP; Holloway RW; Finkler NJ; Ortiz BH; Bigsby IV GE; Ahmad S; DeNardis S. Clinical-Pathologic and Morbidity Analyses of Type 2 and Abdominal Radical Hysterectomy for Cervical Cancer. *Gynecol. Oncol.* 104 (2007) (3, Suppl.1): S24
 19. Schilder RJ; Lokshin AE; Holloway RW; Alvarez RD; Pathak H; Aghajanian C; Drescher CW; Godwin AK: Phase II Trial of Single-Agent Cetuximab in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma with the Potential for Dose Escalation to Rash. American Society of Clinical Oncology June 1-5, 2007. Poster Presentation, Abstract 5577.
 20. Colombo N; McMeekin S; Schwartz P; Kostka J; Sessa C; Gehrig P; Holloway R; Braly P; Matei D; Einstein M: A Phase II Trial of the mTOR Inhibitor AP23573 as a Single Agent in Advanced Endometrial Cancer. American Society of Clinical Oncology June 1-5, 2007. Poster Presentation, Abstract 5516.
 21. DeNardis SA; Holloway RW; Bigsby IV GE; Pikaart DP; Ahmad S; Finkler NJ (2008) Comparison of Robotic-Assisted Laparoscopic versus Total Abdominal Hysterectomy and Lymphadenectomy for Endometrial Cancer. *Gynecol. Oncol.* 108 (3, Suppl.1): A790.

22. Ingersoll SB; Patel S; Monahan KA; Caballero L; DeNardis SA; Ahmad S; Holloway RW; Edwards JR (2008) Synergistic Cytotoxicity of IFN α -2b and IL-2 in Combination with PBMC against Ovarian Cancer: Development of an Experimental Model for Cellular Therapy. *Gynecol. Oncol.* 108 (3, Suppl.1): A322.
23. Tran T; Holloway RW; Finkler NJ (2008): Metastatic Appendiceal Mucinous Adenocarcinoma to Well-Differentiated Diffuse Mesothelioma of the Peritoneal Cavity. *A mimicker of florid mesothelial hyperplasia in association with neoplasms.*
24. Teoh D; Holloway RW; Cohen J; Gu M; Ricketts W; Hu JM; Shin JY; Powell CB; Chen L; Chan JK; (2008) American Society of Clinical Oncology (ASCO) Annual Meeting. The Association of ERCC1 and Clinical Outcomes of Women with Advanced Ovarian Cancer. Abstract No. 5575. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 5575).
25. Holloway RW; Ahmad S; DeNardis SA; Sultana N; Bigsby GE; Pikaart DP; Finkler NJ. Robotic-assisted Laparoscopic Hysterectomy with Lymphadenectomy for Endometrial Cancer: The learning curve and beyond. *Gynecol. Oncol.* 2009; 112 (Suppl.1), A337.
26. Holloway RW; Grendys EC; McMeekin S. Tolerability, Efficacy and Safety of Pegylated Liposomal Doxorubin in Combination with Carboplatin Versus Gemcitabine/Carboplatin for the Treatment of Platinum-sensitive Recurrent Ovarian Cancer: A systematic review. *Gynecol. Oncol.* 2009; 112 (Suppl.1): A316.
27. Ingersoll SB; Ahmad S; Patel S; Edwards D; Patel D; Caballero L; Holloway RW; Edwards JR. Functional Characterization of Fluorescent Highly Tumorigenic Cell Line to use in an Animal Model of Ovarian Cancer. *Gynecol. Oncol.* 2009; 112 (Suppl.1): A208.
28. Pant A; Diaz-Montes T; Tanner E; McCormick CC; Ahmad S; Giuntoli RL; Holloway RW; Bristow RE. The use of Extreme Drug Resistance Assay in Predicting Success with Intraperitoneal Chemotherapy for Advanced Ovarian Cancer. *Gynecol. Oncol.* 2009; 112 (Suppl.1): A124.
29. Ingersoll SB, Yue P, Ahmad S, Turkson J, Edwards JR, Holloway RW. Molecular Characterization of Highly Tumorigenic Cell Lines Used in a Xenograph Model to Investigate Cellular Therapy for the Treatment of Refractory Ovarian Cancer. *J. Clin. Oncol.*, 2009; 27 (Suppl.): e-16516.
30. Holloway RW. The Florida Hospital 3-year experience with robotic surgery in gynecologic oncology. *Proc. 1st. Eur. Symp. Robotic Gynaecol. Surg.*, Milan, Italy (September 16-19, 2009), p. 6.

31. Holloway RW, Finkler NJ, Bigsby IV GE, McCollough B, Peterson LB, Rakowski JA, Ahmad S. Robotic-assisted surgery for early-stage ovarian and tubal malignancies. *Proc. 1st. Eur. Symp. Robotic Gynaecol. Surg.*, Milan, Italy (September 16-19, 2009), p. 29.
32. Holloway RW, Ahmad S, Sultana N, Bigsby IV GE, DeNardis SA, Peterson LB, Finkler NJ. BMI-controlled evaluation of clinico-pathological factors and surgical outcomes of patients with endometrial cancer: Robotic vs. open hysterectomy with lymphadenectomy. *Proc. 1st. Eur. Symp. Robotic Gynaecol. Surg.*, Milan, Italy (September 16-19, 2009), p. 26-27.
33. Holloway RW, Kendrick JE, Peterson LB. "Minimizing" robotic-assisted laparoscopic hysterectomy: The 3-port technique. *Proc. 1st. Eur. Symp. Robotic Gynaecol. Surg.*, Milan, Italy (September 16-19, 2009), p. 28.
34. Holloway RW, Ahmad S, Bigsby IV GE, Peterson LB, Ghurani GB, Lester M, Finkler NJ. Analyses of factors associated with the performance of total abdominal versus robotic-assisted laparoscopic hysterectomy for endometrial cancer. *Gynecol. Oncol.* 2010; 116 (Supp.1): A209.
35. Alvarez Secord A, Watson D, Holloway RW, Geller MA, Gehrig PA, O'Malley DM, Bae-Jump V, Cohn DE, Finkler NJ, Havrilesky LJ. The role of adjuvant therapy in women with optimally cytoreduced stage IIIC endometrial cancer. *Gynecol. Oncol.* 2010; 116 (Supp.1): A202.
36. Alvarez Secord A, Berchuck A, Higgins R, Nucum L, Kohler M, Puls L, Holloway RW, Lewandowski G, Valea F, Havrilesky L. A multicenter, randomized, phase II study evaluating the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer. *Gynecol. Oncol.* 2010; 116 (Suppl. 1), A3.
37. Holloway RW. Incorporating robotics into your practice: Tips for para-aortic lymphadenectomy. Sunrise Session-1 at the 41st Annual Meeting on Women's Cancer of the Society of Gynecologic Oncologists (SGO), March 15, 2010, San Francisco, CA [Course Director: Robert W. Holloway, MD].
38. Ingersoll SB, Ahmad S, Patel S, Ahmed A, Edwards JR, Finkler NJ, Holloway RW. Development of an experimental model to test cellular therapy in combination with cytokines as a novel treatment for ovarian cancer. Accepted for 2010 AACR Annual Meeting. Abstr.# 5749), In Press.
39. Basha MR, Ingersoll SB, Ahmad S, Baker CH, Edwards JR, Holloway RW, Abdelrahim M. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and surviving through expressing the transcription factor Sp1 and Sp3. Accepted for 2010 AACR Annual Meeting (Abstr.# 3996), In Press.

40. Gaia G, Ahmad S, Finkler NJ, Bigsby GE, Peterson LB, Rakowski JA, Holloway RW. Robotic-assisted hysterectomy (RAH) with bilateral salpingo-oophorectomy (BSO) for patients with stage IV endometriosis affected by severe chronic pain syndrome. Oral Presentation at the *World Robotic Gynecology Congress (WRGC)* April 11-14, 2010, Orlando, FL
41. Holloway RW. Whether it's benign or cancer surgery: Pulling it all together with tips & tricks for avoiding complications. Oral Presentation at the *World Robotic Gynecology Congress (WRGC)* April 11-14, 2010, Orlando, FL
42. Ingersoll SB, Stoltzfus GP, Ahmad S, Edwards JR, Finkler NJ, Holloway RW. Differential cytotoxicity response elicited by UCB and PBMC against ovarian cancer cells. *Cytotherapy* 2010; Abstr. # 32.
43. Krasner C, Roche M, DeMars L, Williams J, Enke A, Klien A, Linke R, Holloway RW. Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian cancer after a complete response to chemotherapy: A phase II study. *J. Clin. Oncol.* 2010; Suppl. 1: A5015 [Presenter/Discussant: Robert W. Holloway, MD].
44. Bigsby IV GE, Holloway RW, Ahmad S, Sombeck MD, Ebra G, Finkler NJ. Chemoradiation followed by adjuvant hysterectomy for the treatment of stage IB-2 cervix cancer: 10-year experience. *J. Clin. Oncol.* 2010; Suppl. 1: A5117.
45. Basha RM, Ingersoll SB, Ahmad S, Baker CH, Edwards JR, Holloway RW, Abdelrahim M. Tolfenamic acid inhibits ovarian cancer cells growth by targeting specificity protein transcription factors and decreasing the expression of c-met and surviving. *J. Clin. Oncol.* 2010; Suppl. 1: Abstr.# e15516.

PUBLICATIONS (Full Articles):

1. Beebe S; Holloway RW; Rannels SR; Corbin JD: Two Classes of Cyclic AMP Binding Sites of Type II Protein Kinase Demonstrate Synergism When Added Together to Intact Adipocytes. *J. Biol. Chem.*, 256:6, 1984.
2. Orr JW; Varner RE; Kilgore LC; McDiramid M; Holloway RW: Cefotan versus Cefoxitin as Prophylaxis in Hysterectomy. *Am. J. Obstet. Gynecol.* 154:960-3, 1986.
3. Barter JF; Orr JW; Holloway RW; Hatch KD; Shingleton HM: Psammoma Bodies in Cervicovaginal Smear Associated with an Intrauterine Device. *J. Reproduct. Med.* 32:147-8, 1987.
4. Bater JF; Mazur MW; Holloway RW; Katch KD: Cervical Melanosis. *Gynecol. Oncol.* 29:101-4, 1988.
5. Holloway RW; Barnes WA; Barter JF: The Carbon Dioxide Laser- A Guide to Its Use in Lower Genital Tract Disorders, Part I. *Female Patient* 13(8):63-73, 1989.

6. Holloway RW; Barnes WA; Barter JF: The Carbon Dioxide Laser- A Guide to Its Use in Lower Genital Tract Disorders, Part II. *Female Patient* 13(7):74-89, 1989.
7. Holloway RW; To A; Moradi M; Boots L; Watson N; Shingleton HM: Monitoring the Course of Cervical Carcinoma with the Squamous Cell Carcinoma Serum Radioimmunoassay. *Obstet. Gynecol.* 74:944, 1989.
8. Lewandowski G; Torrissi JR; Potkul RK; Holloway RW; Popescu G; Whitfield G; Delgado G: Hysterectomy with Extended Surgical Staging and Radiotherapy Versus Hysterectomy Alone and Radiotherapy in Stage I Endometrial Cancer: A Comparison of Complication Rates. *Gynecol. Oncol.* 36: 401-404, 1990.
9. Lewandowski G; Delgado G; Holloway RW; Farrell M; Jenson B; Lancaster WD: The Use of In Situ Hybridization to Show Human Papillomavirus Deoxyribonucleic Acid in Metastatic Cancer Cells within Lymph Nodes. *Am. J. Obstet. Gynecol.* 163: 1333-7, 1990.
10. Holloway RW; Farrell MP; Barnes WA; Lewandowski GE; Jenson B; Santos C; Delgado G: Demonstration of Human Papillomavirus Type 16 in Recurrent Cervical Cancer Following Radiation Therapy Using In Situ Hybridization. *Gynecol. Oncol.* 41:123-128, 1991.
11. Orr JW; Holloway RW; Orr PF; Holimon JL: Surgical Staging of Uterine Cancer. An analysis of perioperative morbidity. *Gynecol. Oncol.* 42: 209-216, 1991.
12. Orr JW; Holloway RW: Surgical Aspects of Cervical Cancer. *Surg. Clin. N. Am.* 71(5):1067-83, 1991.
13. Orr JW; Barrett JM; Orr PF; Holloway RW; Holiman JL: The Efficacy and Safety of the Cytobrush during Pregnancy. *Gynecol. Oncol.* 44:260-262, 1992.
14. Pirkowski M; Holloway RW; Delgado G; Barnes W; Thomas D; Torrissi J; Popescu G; Rogers J; Dritchilo A: Radiotherapy of Malignant Subdiaphragmatic Implants in Advanced Ovarian Carcinoma: A New Technique. *Int. J. Radiat. Oncol. Biol. Phys.* 22: 1105-1108, 1992.
15. Holloway RW; Orr JW: An Evaluation of Groshong Central Venous Catheters on a Gynecologic Oncology Service. *Gynecol. Oncol.* 56: 211-217, 1995.
16. Holloway RW; Orr JW: Letters to the Editor. *Gynecol. Oncol.* 49: 407-408, 1993.
17. Fiorica J; Grendys E; Holloway RW; Orr JW; Ndubisi B; DeCesare S; LaPolla J; Boothby R; Hoffman M; Arrango H: Phase II Trial of Topotecan Combined with Cisplatin in Squamous and Non-Squamous Cervical Cancer, Preliminary Results. *Gynecol. Oncol.* 1441, 1999.

18. Holloway RW; Mehta RS; Finkler NJ; Li K-T; McLaren CE; Parker RJ; Fruehauf JP: Association between *in Vitro* Platinum Resistance in the EDR Assay and Clinical Outcomes for Ovarian Cancer Patients. *Gynecol. Oncol.* 87:8-16, 2002.
19. Holloway RW: Treatment Options for Endometrial Cancer: Experience with Topotecan. *Gynecol. Oncol.* 90: S28-S33, 2003.
20. Holloway RW; Herzog TJ; Stuart G: Workshop: Options for Treatment in Ovarian Cancer. *Gynecol. Oncol.* 90: S45-S50, 2003.
21. Rader JS; Clarke-Pearson D; Moore M; Carson L; Holloway RW; Kao MS; Wiznitzer I; Douglass EC: A Phase II Study to Determine the Efficacy and Tolerability of Intravenous ZD9331 in Heavily Pre-Treated Patients with Ovarian Cancer. *Gynecol. Oncol.* 91:318-325, 2003.
22. Bigsby IV G; Holloway RW; Weppelmann B; Reynold RB: Endometrioid Adenocarcinoma of the Uterus with Cardiac Metastasis. A case report and six-year followup. *Gynecol. Oncol.* 97:256-259, 2005.
23. Tran A, Ortiz BH, Holloway RW, Bigsby G, Finkler NJ. Primary Alpha Fetoprotein-Producing Endometrial Papillary Serous Carcinoma Metastasizing to the Ovaries, Mimicking Primary Ovarian Yolk Sac Tumor. *Int. J. Gynecol. Pathol.* 26(1):66-70, 2007.
24. Pikaart, DP; Holloway RW; Ahmad S; Finkler NJ; Bigsby IV GE; Ortiz BH; DeNardis SA. Clinical-Pathologic and Morbidity Analyses of Types 2 and 3 Abdominal Radical Hysterectomy for Cervical Cancer. *Gynecol. Oncol.* 107: 205-210, 2007.
25. Holloway RW; Finkler NJ; Pikaart DP; Bigsby IV GE; DeNardis SA; Ahmad S. Comparison of Total Laparoscopic and Abdominal Radical Hysterectomy for Patients with Early-Stage Cervical Cancer (Letter-to-the-Editor). *Obstet. Gynecol.* 110: 1174-1175, 2007.
26. Tran T; Holloway RW; Finkler NJ. Metastatic Appendiceal Mucinous Adenocarcinoma to Well-Differentiated Diffuse Mesothelioma of the Peritoneal Cavity: A Mimicker of Florid Mesothelial Hyperplasia in Association with Neoplasms. *Int. J. Gynecol. Pathol.* 27: 526-530, 2008.
27. ACOG Update (An Approved System for CME); Robot Surgery. Discussant. Volume 34, section 2, August 2008.
28. DeNardis SA, Holloway RW, Bigsby IV GE, Pikaart DP, Ahmad S, Finkler NJ. Robotically assisted laparoscopic hysterectomy versus total abdominal hysterectomy and lymphadenectomy for endometrial cancer. *Gynecol. Oncol.* 111: 412-417, 2008.

29. Ingersoll SB, Patel S, Caballero L, Ahmad S, Edwards D, Holloway RW, Edwards JR. Synergistic cytotoxicity of interferon- α 2b and interleukin-2 in combination with PBMC against ovarian cancer: Development of an experimental model for cellular therapy. *Gynecol. Oncol.* 112: 192-198, 2009.
30. Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. *Gynecol. Oncol.* 113: 21-27, 2009.
31. Mendivil A, Holloway RW, Boggess JF. Emergence of robotic assisted surgery in gynecologic oncology. *Gynecol. Oncol.* 114: S24-S31, 2009.
32. Holloway RW, Patel SD, Ahmad S. Robotic surgery in gynecology. *Scand. J. Surg.* 98: 96-109, 2009.
33. Holloway RW, Ahmad S, DeNardis SA, Peterson LB, Sultana N, Bigsby IV GE, Pikaart DP, Finkler NJ. Robotic-assisted laparoscopic hysterectomy with lymphadenectomy for endometrial cancer: Analysis of surgical performance. *Gynecol. Oncol.*, 115: 447-452, 2009.
34. Holloway RW. Letter to the Editor: Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer. *Gynecol. Oncol.* 116, 147-148, 2010.
35. Pant AC, Diaz-Montes T, Tanner E, Ahmad S, Giuntoli L, Holloway RW, Bristow RE. Correlation of extreme drug resistance assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer. *J. Chemother.* 22 (4), 2010, In Press.

CONTRIBUTIONS TO BOOKS AND MANUAL:

1. Orr Jr JW and Holloway RW: Intraoperative Techniques in Gynecologic Survey, Chapter 36. In *Textbook of Gynecology*, Copeland L. ed., WB Saunders Company, 1993.
2. Orr Jr. JW and Holloway RW: Postoperative Care in Gynecologic Surgery, Chapter 35. in *Textbook of Gynecology*, Copeland L. ed., WB Saunders Company, 1993.
3. Orr Jr JW and Holloway RW: Perioperative Care, Chapter 49, pp 741-52. In *Gynecology and Obstetrics: A Longitudinal Approach*. Moore, Reiter, Rebar & Baker Editors. Churchill Livingstone, Inc. 1993.
4. Orr Jr JW, Barrett JR, and Holloway RW: Neoplasia in Pregnancy, Chapter 24, pp 385-95. In *Gynecology and Obstetrics: A Longitudinal Approach*. Moore, Reiter, Rebar and Baker Editors. Churchill Livingstone, Inc. 1993.

LECTURES/PRESENTATIONS:

- 02/17/95 Home Therapy Nursing Society of Central Florida: "Ovarian Cancer Update"
- 08/19/95 Oncology Nursing Society of Central Florida: "Update Ovarian Cancer"
- 09/14/95 University of Central Florida, Nurse Practitioner Organization: "Colposcopy of the Female Lower Genital Tract"
- 09/29/95 Grand Rounds, Department of Obstetrics and Gynecology, University of Minnesota: "Modern Evaluation and Management of the Adnexal Mass"
Resident/Fellow Teaching Lecture "Bedside Placement of the Groshong Catheter"
- 12/08/95 Florida Hospital/Waterman: "Surgical Staging of Endometrial Cancer"
- 05/10/96 Florida Radiation Technician Annual Meeting: "Update in Gynecology Oncology"
- 04/29/97 AMGEN Corporation, Atlanta, Georgia - Eastern United States Sales Force Meeting: "Modern Therapy of Ovarian Cancer, Dose Intensity Issues"
- 06/26/97 Port Smith Naval Hospital, Port Smith, VA, Grand Rounds: "Ovarian Cancer Management Issues"
- 06/27/97 Grand Rounds, Chesapeake General Hospital, Chesapeake, VA: "Ovarian Cancer Management Issues"
- 07/23/97 Grand Rounds, Halifax Hospital, Daytona Beach Grand Rounds: "Surgical Staging of Endometrial Carcinoma"
- 09/24/97 Holmes Regional Medical Center, Melbourne, FL, Grand Rounds: "Management of Advanced Staged Cervical Cancer"
- 01/16/98 Halifax Medical Center, Daytona Beach, Grand Rounds: "Controversies in Management of Ovarian Cancer"
- 10/27/98 American College of Surgeons, Annual Meeting, Orlando, FL: "Oophorectomy, Considerations for the General Surgeon"
- 09/22/99 Seminole County Medical Society, Heathrow, FL: "Gynecologic Cancer Screening."
- 01/29/00 Central Florida OB/GYN, Orlando, FL: "Tamoxifen Clinical Trials."

- 03/16/00 Winter Meeting of the Society Gynecologic Oncologists, Salt Lake City, Utah: “Ovarian Cancer Patients with In Vitro Resistance to Platinum.”
- 03/01/01 Society of Gynecologic Oncologists, Nashville, TN: “Association Between In Vitro Platinum Resistance in the EDR Assay and Clinical Outcomes for Ovarian Cancer Patients.”
- 07/19/01 Gynecologic Oncology Group, Cincinnati, Ohio: “Patients with Persistent/Recurrent Ovarian Cancer Should Receive a Regimen Chosen by an In-Vitro Assay.” Pro Argument
- 12/07/02 Global Hycamtin Clinical Workshop, Hollywood, Florida: “Treatment of Advanced Recurrent Metastatic Endometrial Carcinoma with Weekly Topotecan (Hycamtin)”.
- 12/18/03 Interview and presentation by Robert W Holloway with News 13. Topic: FHCI MD Brings Healing Touch to Central Africa
- 07/29/05 GlaxoSmithKline Protocol Workshop - Orlando, Florida: “Overview of Data from a Dose Escalating Trial of Weekly Hycamtin in Recurrent Endometrial Cancer”.
- 08/29/05 Charles E. Flowers Society Meeting - Edinburgh, Scotland: “Prevention of Surgical Adhesions in Gynecologic Abdominal Surgery”.
- 03/2006 Holloway, RW, Finkler, NJ, Nye, L, Bigsby, G, Ortiz, BH. Pegylated Liposomal Doxorubicin and Gemcitabine Therapy for Recurrent Ovarian Cancer; Updated Analysis of Outcomes and Long-term Survival. Poster Presentation SGO, 2006.
- 08/2007 Grand Rounds, Department of OB/GYN- Orlando Regional Medical Center: “Postsurgical Adhesive Disease: Precaution Strategies for the Abdominal Pelvic Surgeon”. Resident/Fellow Teaching Lecture.
- 01/10/08 Intuitive Surgical Systems, Inc.; National Sales Meeting, Invited Lecturer. “Introduction of Robotic Surgery in a Gynecologic Oncology Private Practice”. Las Vegas, NV.
- 01/29/08 Intuitive Surgical Systems, Inc.; Georgetown University Gynecologic and Oncology Alumni Association. “Introduction of Robotic Surgery in a Gynecologic Oncology Private Practice”. Tampa, FL.
- 02/11/08 Intuitive Surgical Systems, Inc.; Latin American Sales Distributors. Robotic Surgery Applications in Gynecology and Gynecologic Oncology. Ft. Lauderdale, FL.
- 02/27/08 Lecture – Robotic Surgery Application in Gynecology and Gynecologic Oncology. Holmes Regional OB/GYN staff. Melbourne, FL.

- 03/18/08 Lecture/Testimony - Centers for Medicare/Medicaid Services (CMS); Robotic Surgery Applications in Gynecology and Gynecologic Oncology. Baltimore, MD.
- 05/05/08 American College of Obstetricians and Gynecologists (ACOG); Robotic Surgery Applications in Gynecology and Gynecologic Oncology. Round Table Audio Digest Recording in Gynecology and Gynecologic Oncology. New Orleans, LA.
- 06/11-14/08 Western Association of Gynecologic Oncologists (WAGOS); Robotic Surgery Applications in Gynecology and Gynecologic Oncology - Robotic Surgery Course Director. Sonoma, CA.
- 10/8-9/08 University of Michigan, Ann Arbor. Robotic Surgery Course Lecture/Proctor.
- 10/28/08 University of Sao Paulo, Brazil; Guest Lecturer/Live Surgery. Latin American Robotic Surgery Congress.
- 01/2009 Faculty/Speaker, Advanced Robotic Training Course, Sunnyvale, CA
- 04/2009 Program Co-Director/Speaker, World Robotic Symposium (A Multidisciplinary Gynecologic Conference), Disney Yacht & Beach Club Resort, Orlando, FL
- 08/2009 Faculty/Speaker, World Robotic Symposium-Latin America, Sao Paulo, Brazil
- 09/2009 Distinguished Faculty, Session Moderator & Speaker, at 1st European Symposium in Robotic Gynaecological Surgery (organized by the Society of European Robotic Gynaecological Surgery) at European Institute of Oncology, Milan, Italy
- 12/2009 Keynote Speaker in Gynecology, at 1st Japan Robotic Surgery Society Conference, organized by Tokyo Medical University, Tokyo, Japan
- 02/05/10 Speaker Winter Meeting of the Society of Gynecologic Oncologists, Salt lake City, Utah; “Tips and Tricks for Robotic Para-aortic Lymphadenectomy”
- 03/2010 Course Director & Speaker, Sunrise Session 1 “Incorporating Robotics Into Your Practice: Tips on Para-Aortic Nodes”, at the Society of Gynecologic Oncologists 41st Annual Meeting on Women’s Cancer™, San Francisco, CA
- 04/2010 Co-Director, Speaker, Session Moderator & Live Surgery/Primary Surgeon at the *World Robotic Gynecology Congress II (WRGCII) & International Gynecologic Oncology Robotic Symposium III (IGORSIII)*, April 11-14, 2010, Orlando, FL

Upcoming Presentations

- 06/2010 Poster Presenter/Discussant at the Annual Meeting of the American Society of Clinical Oncology (ASCO), June 4-8, 2010, Chicago, IL; “Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian-cancer after a complete response to chemotherapy: a phase II study”.
- 6/25/10 Faculty, “2010 GOG/SGO/ASCO Update”, Hyatt Regency Grand Cypress, Orlando, FL
- 07/15/10 Keynote Speaker in Gynecology Oncology - 2010 Yonsei da Vinci® Live Symposium Robotic Surgery Conference, Seoul, South Korea, “State of the Art Robotic Surgery in Gynecologic Oncology”
- 07/2010 Invited Faculty/Speaker, World Robotic Symposium-Latin America, Sao Paulo, Brazil, “Avoiding complications in Robotic Surgery”, “Tips for Success with Robotic Para-aortic Lymphadenectomy”, and “Robotic Radical Hysterectomy Video Tutorial”
- 07/31/10 Keynote Speaker in Gynecology, 50th Congress of the Japan Society of Gynecologic and Obstetric Endoscopy and Minimally Invasive Therapy, Tokyo, Japan, “State-of-the-Art Robotic Surgery in Gynecologic Oncology”
- 09/2010 Distinguished Guest Faculty, Session Co-Chair & Speaker, at 2nd European Symposium in Robotic Gynaecological Surgery (organized by the Society of European Robotic Gynaecological Surgery), September 9-11, 2010, Lund, Sweden

Revised: 4/21/10